Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Other Accumulated Expenses (2019 - 2025)

Benitec Biopharma has reported Other Accumulated Expenses over the past 7 years, most recently at $62000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $62000.0 for Q4 2025, down 32.61% from a year ago — trailing twelve months through Dec 2025 was $62000.0 (down 32.61% YoY), and the annual figure for FY2025 was $67000.0, down 51.45%.
  • Other Accumulated Expenses reached $62000.0 in Q4 2025 per BNTC's latest filing, down from $147000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $223000.0 in Q4 2021 and bottomed at $36000.0 in Q1 2023.
  • Median Other Accumulated Expenses over the past 5 years was $76500.0 (2023), compared with a mean of $96050.0.
  • The largest annual shift saw Other Accumulated Expenses plummeted 81.61% in 2022 before it skyrocketed 149.15% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $223000.0 in 2021, then crashed by 81.61% to $41000.0 in 2022, then surged by 80.49% to $74000.0 in 2023, then rose by 24.32% to $92000.0 in 2024, then tumbled by 32.61% to $62000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for BNTC at $62000.0 in Q4 2025, $147000.0 in Q3 2025, and $67000.0 in Q2 2025.